Work

Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.5_suppl.25

Authors: Susan F. Slovin, Omid Hamid, Sheela Tejwani, Celestia S. Higano, Andrea Harzstark, Joshi J. Alumkal, Howard I. Scher, Kevin M. Chin, Paul Gagnier, M. Brent McHenry, Tomasz M. Beer

Institutions: Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, Henry Ford Hospital, Bristol-Myers Squibb (United States), Angeles Clinic and Research Institute, Sidney Kimmel Center for Prostate and Urologic Cancers

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2563849899

Cites:

Cited by: 16

Related to: 10